Opinion
Video
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Author(s):
Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer (nmCRPC) show darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.
Timecodes
1:30 ARIs in Prostate Cancer
7:40 Experience with ARIs in PC
12:05 Use of PC RWD in Practice
16:00 DEAR Study in nmCRPC
20:55 DEAR Race Subgroup Analysis
25:00 Other ARI RWD in nmCRPC
27:45 Interpreting & Using RWD
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
